Breaking The Old 52 Week Low, MEREO BIOPHARMA/ADR (Nasdaq:MREO) Finishing At $3.41

MREO
MREO

MEREO BIOPHARMA/ADR (Nasdaq:MREO)

June 13th, 2019

Amidst rising markets MEREO BIOPHARMA/ADR finished Thursday’s trading session down 13.01%, a ($0.51) decrease to close on $3.41. As well as the drop in value, MEREO BIOPHARMA/ADR hit a new 52 week low of $3.34. MEREO BIOPHARMA/ADR bounced 22.75% between low and high. Two technical ‘scores’ for stocks to be aware of are the Altman Z1 and the Piotroski2 scores. MREO scored rather low for both, which could be indicators of trouble down the road (the Altman Z-Score is -2.59, and the Piotroski Score is 2). Despite the drop in value, trading volumes were solid at 207.00% of normal which can indicate investor opportunities.

MREO was outperformed by the rest of the Healthcare sector which went down just -0.11%.

Market Sectors

The market sectors were mixed Thursday with a majority of the sectors trending up. Energy saw the biggest increase of the day (1.25%), while the Healthcare sector saw the biggest drop (-0.11%). Information Technology has seen the biggest year-to-date gain of 23.06%.

Utilities saw the biggest turn-around compared to its 5-day performance (-0.31%), as it went up by 0.15%. Healthcare saw a turn-around from its 5-day performance of 2.18% trading down -0.11%.

Sector Breakdown

  • Energy, up 1.25%.
  • Communication Services, up 1.14%.
  • Consumer Discretionary, up 0.90%.
  • Materials, up 0.58%.
  • Industrials, up 0.54%.
  • Financials, up 0.23%.
  • Information Technology, up 0.22%.
  • Utilities, up 0.15%.
  • Consumer Staples, up 0.11%.
  • Real Estate, up 0.09%.
  • Healthcare, down -0.11%.

MEREO BIOPHARMA/ADR Info

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that MEREO BIOPHARMA/ADR’s score is -2.59) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (MEREO BIOPHARMA/ADR’s score is 2), and 9 is the best.

MREO daily update
MREO daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.